Brain: positron emission tomography tracers beyond [¹⁸F]fluorodeoxyglucose

Tarun Singhal; Abass Alavi; Chun K Kim

doi:10.1016/j.cpet.2014.03.009

Brain: positron emission tomography tracers beyond [¹⁸F]fluorodeoxyglucose

PET Clin. 2014 Jul;9(3):267-76. doi: 10.1016/j.cpet.2014.03.009.

Authors

Tarun Singhal¹, Abass Alavi², Chun K Kim³

Affiliations

¹ Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
² Division of Nuclear Medicine, Department of Radiology, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
³ Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. Electronic address: ckkim@bwh.harvard.edu.

PMID: 25030390
DOI: 10.1016/j.cpet.2014.03.009

Abstract

Several PET radiopharmaceuticals beyond FDG have been used to study the physiology and pathophysiology in neurosciences. This article provides a broad overview of some of the commonly studied radiopharmaceuticals for PET imaging in selected neurologic conditions, particularly attempting to study their clinical relevance. Future studies on the use of advanced PET imaging in delineating neural pathophysiology, drug development, and altering patient management and outcomes across the disciplines of neurosciences are needed.

Keywords: Brain; Central nervous system; Dementia; Epilepsy; Neuroinflammation; Parkinson disease; Positron; Positron emission tomography.

Publication types

Review

MeSH terms

Brain Neoplasms / diagnostic imaging*
Carbon Radioisotopes
Dementia / diagnostic imaging*
Epilepsy / diagnostic imaging*
Fluorine Radioisotopes
Humans
Movement Disorders / diagnostic imaging*
Positron-Emission Tomography / methods*
Radiopharmaceuticals

Substances

Carbon Radioisotopes
Fluorine Radioisotopes
Radiopharmaceuticals